Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Feb;31(3):271-85.
doi: 10.1177/0333102410381142. Epub 2010 Sep 22.

Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study

Collaborators, Affiliations
Randomized Controlled Trial

Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study

Joel R Saper et al. Cephalalgia. 2011 Feb.

Abstract

Background: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache ≥15 days per month.

Methods: A multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation (ONS) in CM. Eligible subjects received an occipital nerve block, and responders were randomized to adjustable stimulation (AS), preset stimulation (PS) or medical management (MM) groups.

Results: Seventy-five of 110 subjects were assigned to a treatment group; complete diary data were available for 66. A responder was defined as a subject who achieved a 50% or greater reduction in number of headache days per month or a three-point or greater reduction in average overall pain intensity compared with baseline. Three-month responder rates were 39% for AS, 6% for PS and 0% for MM. No unanticipated adverse device events occurred. Lead migration occurred in 12 of 51 (24%) subjects.

Conclusion: The results of this feasibility study offer promise and should prompt further controlled studies of ONS in CM.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Randomization and study design, three-month overview. Adjustable stim = adjustable stimulation group. Preset stim = preset stimulation group.
Figure 2.
Figure 2.
Disposition of patients in the study. Adjustable stim = adjustable stimulation group. Preset stim = preset stimulation group.
Figure 3.
Figure 3.
Percentage change in number of headache days. Adjustable stim = adjustable stimulation group. Preset stim = preset stimulation group.
Figure 4.
Figure 4.
Change in overall pain intensity. Adjustable stim = adjustable stimulation group. Preset stim = preset stimulation group.
Figure 5.
Figure 5.
Percentage change in number of days with prolonged, severe headache. Adjustable stim = adjustable stimulation group. Preset stim = preset stimulation group.
Figure 6.
Figure 6.
Change in hours of headache per day (averaged over all days). Adjustable stim = adjustable stimulation group. Preset stim = preset stimulation group.
Figure 7.
Figure 7.
Responder rate by treatment group. Adjustable stim = adjustable stimulation group. Preset stim = preset stimulation group.

Comment in

References

    1. Menken M, Munsat TL, Toole JF. The global burden of disease study—implications for neurology. Arch Neurol 2000; 57: 418–420 - PubMed
    1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646–657 - PubMed
    1. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004; 62: 788–790 - PubMed
    1. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 2007; 13: 39–44 - PubMed
    1. Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia 2006; 26: 1168–1170 - PubMed

Publication types